We interview Vetter’s Thomas Otto about his career and the importance of sustainability in the pharma industry.

After other defendants in the case settle, Teva is left to face the music in New York alone.

Experts explain how cell therapies can tackle tumors in our 2021 supplement on cell and gene therapies.

Can ten23 health really make a difference to the planet while fully supporting its biopharma customers? We find out.

AppliedVR gets FDA OK to market virtual reality system for chronic pain.

How will vaccine and therapeutic makers respond to the new SARS-CoV-2 variant?

A quick look at reactions across the US to Biden’s Build Back Better bill.

The latest issue of The Bioprocess Curator included a lot of interesting news about vaccines. In case you missed it, here's some of the top stories.

The FDA has approved just three biosimilars in 2021 – but the approvals could shake up the field as discussions around interchangeability intensify.

Part 2 of our roundtable discussion with CDMOs covers outsourcing preferences, the demand for mRNA, and more.